ERBB2 and cancer: In BC, IA has shown a similar cytotoxic activity among luminal A, HER-2(+), and triple-negative subtypes as well as greater selectivity towards cancer cells, since much less damage was observed in non-tumorigenic cells [10], which suggests that IA could be a compound that meets the characteristics of universality and selectivity necessary to be considered in studies aimed at analyzing its possible use as a phytopharmaceutical for BC.